Single-center experience in 127 adult patients, mono or dual artificial liver support therapy, in patients with acute liver failure

Background Acute liver failure (ALF) is a serious condition characterized by sudden dysfunction, jaundice and hepatic encephalopathy. Its mortality rate of approximately 80% underscores the urgent need for effective treatments. Supportive extracorporeal therapies (SET), which temporarily support function remove toxins, have shown promise in improving outcomes acute (ALF). The aim this study was to compare dual supportive therapy (SET) mono patients with failure. Methods A total 127 were included retrospective, single-center study. Of these, 62 received 65 therapy. Primary endpoints survival without transplantation mortality. Secondary resolution encephalopathy normalization International Normalized Ratio (INR). Results In group, 59.6% survived transplantation, while 27.4% achieved recovery transplantation. group 12.9%. Significant regression grade observed 87% patients, 1 year transplant recipients 10.7%. 61.5% experienced successful 29.2%. improvement 70.7% patients. Conclusion Both (CVVHDF PE) (PE) associated significant improvements renal biochemical parameters, blood ammonia levels, neurological status III-IV particular, improved hemodynamic stability, lactic acidosis acid–base balance. Survival our retrospective cohort using protocolized approach higher compared previously published large ALF studies. This warrants further prospective